

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

SPECIFICATION

SUBSTANCE WITH ANTITHROMBIC ACTIVITY AN METHOD FOR
DETECTING GLYCOCALICIN

5

Technical Field

The present invention relates to substance with antithrombotic activity and method for detecting
10 glyco calicin. More precisely, it relates to a method for detecting or measuring a substance that inhibits binding of von Willebrand factor and glycoprotein Ib, and means directly used for carrying out the method.

15

Background Art

The global number of patients with thromboses such as myocardial infarction, cerebral infarction and peripheral artery occlusive disease is very large, and
20 these diseases are very significant diseases to be diagnosed and treated. Platelets play a fundamental role for the onset of these thromboses. In general, if vascular endothelial cells in blood vessel cavities are impaired by arteriosclerotic lesion or the like,
25 platelets will adhere to the impaired region to cause activation, and thus there are formed thrombocytic thrombi, which eventually develop into occlusive lesions.

As one of the methods for detecting activation of platelets, there is a method of measuring glyocalicin concentration in plasma. Glyocalicin is a protein consisting of an enzymatically cleaved extracellular portion of a membrane glycoprotein present on surfaces of platelets, glycoprotein Iba chain, and has a molecular weight of about 135 kDa. It is known that glyocalicin concentration in plasma is increased by impairment or activation of platelets, and it is currently used as a marker for detecting presence or absence of thrombotic diseases in clinical diagnosis. (J.H. Beer et al., *Blood*, 83, 691-702, 1994; S. Kunishima et al., *Clin. Chem.*, 37, 169-172, 1991).

Many measurement methods of glyocalicin concentration have been reported, and any of these are based on ELISA (enzyme-linked immunosorbent assay) technique, wherein glyocalicin is detected by the sandwiching method utilizing two kinds of monoclonal antibodies directed to glyocalicin (J.H. Beer et al., supra; S. Kunishima et al., supra). Briefly, first monoclonal antibodies are immobilized on a 96-well plate or the like as a solid phase, blocked with a protein such as bovine serum albumin (BSA), and then added with patient's plasma (or serum) to be measured. Glyocalicin specifically binds to the monoclonal antibodies immobilized on the solid phase. The plate is washed, and added with second monoclonal antibodies

labeled with an enzyme such as alkaline phosphatase and peroxidase or biotin so that the second antibodies should specifically bind to the glyocalicin bound to the first monoclonal antibodies. After washing, the plate is added with a substrate that can be converted into a substance exhibiting specific absorbance in a UV or visible region, fluorescence or luminescence with the enzyme used as the label of the second antibodies to perform an enzymatic reaction. Since the amount of glyocalicin in the patient's plasma and the binding amount of the second antibodies show positive correlation, the concentration of glyocalicin in the patient's plasma can be measured by quantifying the reaction product produced by the enzymatic reaction. A measurement method for glyocalicin by competitive ELISA utilizing one kind of anti-glyocalicin antibodies has also been reported (H. Bessos et al., *Thromb. Res.*, 59, 497-507, 1990). However, the IC_{50} value of the glyocalicin concentration showing competitive inhibition is about 4 $\mu\text{g/ml}$, and this makes the above measurement unusable for the measurement of the glyocalicin concentration in plasma (it is about 2 $\mu\text{g/ml}$ in a healthy subject, J.H. Beer et al., *supra*).

The aforementioned glyocalicin quantification methods based on the sandwich technique are widely used at present. However, when a similar measurement system is desired to be newly prepared, it is necessary to

obtain two kinds of anti-glycocalicin monoclonal antibodies having different recognition sites. Commercially available monoclonal antibodies are generally very expensive, and the preparation of

5 monoclonal antibodies requires much labor such as acquisition of glycocalicin for immunization, acquisition of hybridoma from a spleen of immunized mouse and screening of a monoclonal antibody-producing cell. Further, it is impossible to measure an absolute

10 value of glycocalicin concentration from the amount of the enzymatic reaction in the aforementioned sandwich ELISA method, and in many cases, it is necessary to measure glycocalicin of several kinds of known concentrations to obtain a calibration curve, and then

15 it is necessary to calculate a concentration in a test sample to be measured based on comparison with the calibration curve. Therefore, it is important to establish a method capable of measuring an absolute concentration of glycocalicin in a simple manner without

20 the complicated preparation of monoclonal antibodies, from a viewpoint of wide use in clinical diagnosis.

Further, in an early stage of onset of thrombosis, von Willebrand factor in blood binds to subendothelial tissues (collagen etc.) exposed due to impairment of

25 vascular endothelial cells, and the membrane glycoprotein, glycoprotein Ib, on platelets binds to the von Willebrand factor. Thus, the platelets adhere to

blood vessel walls, and they are activated (J.P. Cean et al., *J. Lab. Clin. Med.*, 87, 586-596, 1976; K.J.

Clemetson et al., *Thromb. Haemost.*, 78, 266-270, 1997).

Therefore, it is an important target of antithrombotic drugs for treating or preventing thromboses to inhibit the binding of von Willebrand factor and glycoprotein Ib. However, there are few substances that have been proven to exhibit antithrombotic property by inhibiting the binding of the both proteins.

10 It has been reported that a recombinant protein VCL that has a sequence of from the 504th to 728th amino acid residues of von Willebrand factor shows an antithrombotic action by inhibiting the binding of von Willebrand factor and glycoprotein Ib (K. Azzam et al.,
15 *Thromb. Haemost.*, 73, 318-323, 1995). Further, it has also been reported that a monoclonal antibody AJvW-2 directed to human von Willebrand factor exhibits an antithrombotic activity by specifically binding to von Willebrand factor without showing hemorrhagic tendency
20 (S. Kageyama et al., *Br. J. Pharmacol.*, 122, 165-171, 1997; WO 96/17078). Furthermore, the protein AS1051 derived from snake venom specifically binds to the platelet glycoprotein Ib to similarly exhibit an antithrombotic property without showing hemorrhagic
25 tendency (N. Fukuchi et al., WO 95/08573).

Further, aurintricarboxylic acid (ATA), which is a pigmental compound, has been reported to show an

activity for inhibiting the binding of von Willebrand factor and glycoprotein Ib (M.D. Phillips et al., *Blood*, 72, 1989-1903, 1988). However, it is known that its binding specificity is not high (K. Azzam et al., *Thromb. Haemost.*, 75, 203-210, 1996; D. Mitra et al., *Immunology*, 87, 581-585, 1996; R.M. Lozano et al., *Eur. J. Biochem.*, 248, 30-36, 1997), and that the inhibition activity is exhibited by a polymerized macromolecule fraction (M. Weinstein et al., *Blood*, 78, 2291-2298, 1991; Z. Gao et al., *Thromb. Res.*, 71, 77-88, 1993; H. Matsuno et al., *Circulation*, 96, 1299-1304, 1997) etc.

As described above, although it is an important target of antithrombotic drugs to inhibit the binding of von Willebrand factor and glycoprotein Ib, there is no low molecular weight compound that has reported to inhibit the binding of the both and have an antithrombotic activity, and therefore it is important to find out such a substance for attempting treatment and prevention of thromboses.

As a non-proteinaceous substance that inhibits the binding of von Willebrand factor and glycoprotein Ib, aurointricarboxylic acid (ATA) can be mentioned. However, it is known that it exhibits the inhibitory activity as a polymerized macromolecular substance as already described above. M. Weinstein et al. (*Blood*, 78, 2291-2298, 1991) investigated an activity of ATA fractionated by gel filtration for inhibiting the ristocetin-induced

aggregation, which is von Willebrand factor and glycoprotein Ib dependent platelet aggregation, and concluded that a polymer having a molecular-weight of 2500 had the strongest activity. They also showed that fractions eluted as low molecular weight fractions in the gel filtration scarcely have the activity (Figs. 1 and 3 in the aforementioned reference). Moreover, in this report, neither a specific structure nor molecular weight of the ATA polymer showing the activity was specified. It is considered that there are no ATA derivatives exhibiting the inhibitory activity for the binding of von Willebrand factor and glycoprotein Ib among those of which structure can be specified, in view of the facts that, although the synthesis of the ATA monomer has already been reported by R.D. Haugwitz (WO 91/06589), no data were reported so far for demonstrating the inhibition of the binding of von Willebrand factor and glycoprotein Ib as for the monomer or a polymer of which structure can be specified, and evaluation of the activity has been reported by using a gel filtration fraction of ATA polymer even in a recent study (T. Kawasaki et al., *Amer. J. Hematol.*, 47, 6-15, 1994).

In the aforementioned report by M. Weinstein et al. (*Blood*, 78, 2291-2298, 1991), it is described that presence of many negative electric charges (polyanion) and presence of many aromatic rings (polyaromatic) are

necessary for the inhibition of the binding of von Willebrand factor and glycoprotein Ib. The fact that the abundance of ~~negative~~ electric charges is likely to inhibit the binding of von Willebrand factor and glycoprotein Ib is also consistent with the fact that heparin, which is a polysaccharide having negative electric charges, inhibits the binding of von Willebrand factor and glycoprotein Ib (M. Solbel et al., *J. Clin. Invest.*, 87, 1787-1793, 1991). In this report, it is also reported that the activity for inhibiting the binding of von Willebrand factor and glycoprotein Ib is reduced, as the molecular weight of heparin becomes smaller.

Heparin is originally a substance inhibiting thrombin, which is a blood aggregation factor, and the blood aggregation factor X (factor Xa). Although a heparin derivative that was imparted with higher selectivity for the binding of von Willebrand factor and glycoprotein Ib has also been reported (M. Sobel et al., *Circulation*, 93, 992-999, 1996), the average molecular weight of that substance is 10,000 or more.

Among substances that are likely to bind to proteins, there is also reported a substance that shows the selective inhibitory activity to some extent for the binding of von Willebrand factor and glycoprotein Ib. It was demonstrated that Evans Blue, which is a pigmental compound, selectively inhibited the platelet

aggregation in which von Willebrand factor (factor VIII in this reference) was involved (E.P. Kirby et al., *Thrombos. Diathes. Haemorrh.*, 34, 770-779, 1975).

However, the experimental results contained in this reference all concerned platelet aggregation under a condition not containing blood plasma, and no reference was made for the activity under a condition where plasma proteins are present. Evans Blue is originally a substance that very firmly binds to serum albumin, and such a property provides its use as means for measurement of blood volume, blood leak from blood vessels in living bodies and so forth (M. Gregersen & R.A. Rawson, *Physiol. Reviews*, 39, 307, 1959). That is, when treatment of living bodies, for example, humans, is intended, such substances that strongly bind to proteins in plasma as mentioned above would not show the effect at all. As such substances, there are sulfobacin (T. Kamiyama et al., *J. Antibiot.*, 48, 924-928, 1995) and so forth. Although sulfobacin showed the specificity for the binding of von Willebrand factor and glycoprotein Ib to some extent according to the above reference, it must not show the activity due to the binding to plasma proteins in blood or blood plasma in view of its detergent-like structure. In fact, its inhibitory activity for the platelet aggregation in plasma was not shown in the aforementioned reference.

As described above, any low molecular compounds

have not been known so far, which can inhibit the binding of von Willebrand factor and glycoprotein Ib in living bodies. Assuming drugs against thrombotic diseases for inhibiting the binding of von Willebrand factor and glycoprotein Ib, if they are used as an injection, they may be a macromolecular compound such as proteins or polymers. However, in order to create a drug of the same mechanism of action that can be orally administered, it is important to find a low molecular weight substance that is not a polymer and completely and selectively inhibits von Willebrand factor and glycoprotein Ib dependent platelet aggregation in blood (in plasma).

However, such compounds have not been found so far. As a reason for this, there can be mentioned the fact that any assay system enabling screening of such a substance in a simple manner has not existed.

As will be described later, in conventionally used assay methods for detecting the binding of von Willebrand factor and glycoprotein Ib, ^{125}I -labeled von Willebrand factor are bound to platelets or formalin-fixed platelets. However, such methods suffer from complexity of using the radioactive isotope, and difficulty of obtaining a large amount of sample, i.e., difficulty that blood must be collected from an animal, and platelets must be obtained from it. The methods generally used so far and means for solving the problems

thereof will be specifically described below.

The binding of von Willebrand factor and glycoprotein Ib is not observed under a usual condition, and it is considered that it occurs only under a
5 condition where shear stress is induced in a blood flow (T.T. Vincent et al., *Blood*, 65, 823-831, 1985). However, as a method for artificially making it possible to observe the binding of the both proteins, there are known addition of an antibiotic, ristocetin (M.A. Howard
10 and B.G. Firkin, *Thromb. Haemost.*, 26, 362-369, 1971), and addition of a protein derived from snake venom, botrocetin (M.S. Read et al., *Proc. Natl. Acad. Sci. USA.*, 75, 4514-4518, 1978). That is, the both substances are known as a substance that binds to a
15 specific site of von Willebrand factor to cause a structural change of the von Willebrand factor, thereby causing the binding of the von Willebrand factor and glycoprotein Ib, which does not occur under a usual condition. As a method for observing the binding of the
20 both proteins, there is the following method reported by Fujimura et al. (Y. Fujimura et al., *Blood*, 77, 113-120, 1991).

That is, human von Willebrand factor is labeled with ^{125}I in a conventional manner, and allowed to bind
25 to formalin-fixed platelets in the presence of a certain amount of ristocetin or botrocetin. This binding occurs due to the specific binding of the von Willebrand factor

to glycoprotein Ib on the surfaces of the immobilized platelets, and after unbound von Willebrand factor are removed by washing, the amount of the both proteins bound to each other can be measured by measuring the amount of ^{125}I . Miura et al. detected the binding of the both proteins by a similar method, wherein platelets were immobilized on a 96-well plate via immobilized anti-platelet membrane protein antibodies instead of the use of formalin-fixed platelets (S. Miura et al., *Anal. Biochem.*, 236, 215-220, 1996). Further, Matsui et al. reported a method of binding glyocalicin, which is a partial protein of the extracellular portion of glycoprotein Iba chain in the presence of botrocetin, to von Willebrand factor bound to collagen immobilized as a solid phase (T. Matsui et al., *J. Biochem.*, 121, 376-381, 1997). Furthermore, Moriki et al. produced a recombinant protein expressing cell that expressed glycoprotein Ib on the membrane, and reported that ^{125}I -labeled von Willebrand factor bound to the glycoprotein Ib on the membrane in the presence of botrocetin. Moriki et al. further produced a cell expressing glycoprotein Ib having a mutation in the amino acid sequence, which bound to von Willebrand factor without any inducing agent, and performed a binding experiment. However, the binding amount was very small compared with the binding amount in the presence of botrocetin or ristocetin (T. Moriki et al., *Blood*, 90, 698-705, 1997).

As described above, all of the methods reported so far for detecting the binding of von Willebrand factor and glycoprotein Ib with high sensitivity are methods by obtaining a large amount of platelets or glycoprotein Ib expressing cells and detecting the binding of von Willebrand factor to them. However, it is extremely laborious to routinely prepare a large amount of platelets or such cells, and therefore it is necessary to develop a method for detecting the binding of von Willebrand factor and glycoprotein Ib in a simpler manner.

Further, all of the conventionally used methods are exclusively methods utilizing addition of a binding inducing substance such as botrocetin or ristocetin to a liquid phase. However, the amount of botrocetin or ristocetin changes the amount of the binding of von Willebrand factor and glycoprotein Ib. Moreover, if a large number of binding experiments are performed by using a 96-well plate, for example, these methods utilizing addition of the inducing substance to the liquid phase are laborious. Furthermore, when the aforementioned low molecular weight substance inhibiting the binding of von Willebrand factor and glycoprotein Ib is searched, an extremely large number of binding experiments must be performed, and therefore it is also important from this viewpoint to solve the aforementioned problem.

As already stated, a true inhibition substance with low molecular weight for the binding of von Willebrand factor and glycoprotein Ib has not been discovered yet. The term "true inhibition substance" used herein means a substance specifically inhibiting the binding of von Willebrand factor and glycoprotein Ib, but does not mean a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib in a non-specific manner, even though it may inhibit the binding of von Willebrand factor and glycoprotein Ib, like substances that generally change structures of proteins such as protein denaturing substances and detergents or substances that non-specifically bind to proteins.

As described above, such true inhibition substances for the binding of von Willebrand factor and glycoprotein Ib have been found among antibodies, proteins derived from snake venom, pigmental substances such as aurintricarboxylic acid (ATA), of which active body is a substance having a high molecular weight. However, no such substance has been known among low molecular weight substances, for example, those having a molecular weight of 2000 or less, in particular, those having a molecular weight of 1000 or less, which are useful for oral administration. Therefore, it has been desired to develop an evaluation system capable of quickly screening such substances.

Disclosure of the Invention

The problems of the aforementioned technical background are summarized in the following three points.

5 (1) Although methods for quantification of glyocalicin is important for diagnosis of thromboses, conventional highly sensitive methods are sandwich ELISA methods.

Therefore, two kinds of monoclonal antibodies having different recognition sites are required, and a
10 calibration curve prepared with a standard substance is required for the quantification.

(2) It is important to discover a low molecular weight inhibition substance for the binding of von Willebrand factor and glycoprotein Ib, and use it as a drug, in
15 view of the treatment and prevention of thromboses. However, no low molecular weight drug has been known so far, which targets the inhibition of the binding of von Willebrand factor and glycoprotein Ib and is reported to have antithrombotic activity.

20 (3) In order to find out such a drug as mentioned in the above (2), large number of binding inhibition experiments must be performed for von Willebrand factor and glycoprotein Ib. However, the conventionally known methods are complicated, and may have problems
25 concerning accuracy and sensitivity.

The present invention has been accomplished from the aforementioned viewpoints, and an object of the

present invention is to provide a method for detecting the binding of von Willebrand factor and glycoprotein Ib in a simple manner, a simple method for measurement of glyccocalicin, and a simple method for measurement of a substance that can be an antithrombotic drug of which working point is the inhibition of the binding of von Willebrand factor and glycoprotein Ib, as well as means for use in these measurement methods.

The inventors of the present invention assiduously studied in order to achieve the aforementioned object. That is, a protein expression system based on an animal cell was prepared first for obtaining a chimeric molecule consisting of a partial protein of glycoprotein Iba chain bound to the Fc region of immunoglobulin molecule (hereinafter referred to as "chimeric protein"). Further, they found that, if von Willebrand factor was immobilized in the presence of botrocetin, the aforementioned chimeric protein, i.e., glycoprotein Ib molecule, specifically bound to the immobilized von Willebrand factor without a binding inducing substance in a liquid phase, and that a binding test can be performed in a simple manner to measure the binding amount by labeling commercially available inexpensive anti-immunoglobulin Fc antibodies or directly labeling the chimeric protein, and thus accomplished the present invention.

That is, the first method according to the present

invention is a method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of immobilizing von Willebrand factor in a reaction vessel in the presence
5 of a substance inducing the binding of von Willebrand factor and glycoprotein Ib, and, reacting the immobilized von Willebrand factor with glycoprotein Ib.

The second method according to the present invention is a method for detecting binding of von
10 Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of binding a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site
15 of glycoprotein Iba chain at its carboxyl terminus or the chimeric protein labeled with a labeling substance to von Willebrand factor immobilized in a reaction vessel, and detecting the Fc region of the immunoglobulin molecule or the labeling substance.

20 The third method according to the present invention is a method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of immobilizing a chimeric protein that consists of an Fc region of
25 immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl

terminus in a reaction vessel, binding von Willebrand factor or labeled von Willebrand factor to the chimeric protein, and detecting bound von Willebrand factor or the labeling substance.

5 In a preferred embodiment of the second method or the third method, when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the
10 reaction vessel.

As the substance that induces the binding of von Willebrand factor and glycoprotein Ib, botrocetin, ristocetin or the both substances can be mentioned.

15 Further, in another embodiment of the second method, von Willebrand factor is immobilized in the reaction vessel in the presence of a substance that induces the binding of von Willebrand factor and glycoprotein Ib.

20 In the first, second and third methods, glyocalicin contained in a sample can be measured by adding the sample to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or the chimeric protein, or prior to the reaction, and detecting inhibition of the binding of von Willebrand
25 factor and glycoprotein Ib or the chimeric protein.

Further, in the first, second and third methods, a substance that inhibits the binding of von Willebrand

factor and glycoprotein Ib can be detected by adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or the chimeric protein, or
5 prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib or the chimeric protein.



The present invention further provides a chimeric protein, which consists of an Fc region of
10 immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl terminus.

The present invention also provides a kit for
15 measuring glyco-calicin based on inhibition of a reaction of von Willebrand factor and glycoprotein Ib, which comprises von Willebrand factor and a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein
20 comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl terminus.

The present invention further provides a compound which is detected by any of the aforementioned methods for detecting the binding of von Willebrand factor and
25 glycoprotein Ib or inhibition of the binding, and has an activity for specifically inhibiting platelet aggregation involving glycoprotein Ib and von Willebrand

factor in blood plasma and a molecular weight of not more than 2000.

As specific examples of the aforementioned compound, compounds having a structure represented by the formula (I), more specifically, compounds
5 represented by the formula (II) can be mentioned. In the formulae, R^1 and R^2 independently represent H or Cl, and R^3 represents CH_3 or H.



The term "chimeric protein" used in the present specification means a chimeric protein that consists of an ~~Fc~~-region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib at its carboxyl terminus. Further, the term "glycoprotein Ib" used for the methods of the present invention may refer to glycoprotein Ib itself or the chimeric protein, or the both of them.

The term "detection" used in the present specification mainly means finding out a substance or a phenomenon, but it may also mean measurement of amount of the substance or degree of the phenomenon as a result of the finding of the substance or the phenomenon. Further, the term "measurement" mainly means measurement of an amount of substance or a degree of phenomenon, but it may also mean finding out the substance or the phenomenon.

The present invention will be explained in detail hereinafter.

<1> Chimeric protein

The chimeric protein of the present invention is a protein consisting of a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain, which is one of platelet membrane proteins of human or other mammals, bound to an Fc region of a heavy chain (H

chain) of immunoglobulin molecule of mouse, human or other mammals by means of a genetic engineering technique. This chimeric protein can be produced by using cultured cells. In the chimeric protein, the partial protein comprising von Willebrand factor binding site of glycoprotein Iba chain and the Fc region of the immunoglobulin molecule are bound at the carboxyl terminus of the partial protein and the amino terminus of the Fc region.

As an example of the partial protein of glycoprotein Iba chain, there can be mentioned a partial protein having a sequence comprising amino acid residues of from the amino terminus to the aspartic acid residue at the 319th position (amino acid numbers 1-319) of glycoprotein Iba chain molecule. However, since it is considered that von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid numbers 1-293 (V. Vincente et al., *J. Biol. Chem.*, 263, 18473-18479, 1988), and in the sequence of the amino acid numbers 251-285 (V. Vicente et al., *J. Biol. Chem.*, 265, 274-280, 1990), a partial protein containing at least these regions may be sufficient.

Further, the Fc region of immunoglobulin molecule may be derived from any animals, and may be of any subtype, and those that can be purified and/or detected with commercially available polyclonal antibodies and/or monoclonal antibodies, protein A, protein G or the like

may be used. The immunoglobulin heavy chain comprises regions called VH domain, CH1 domain, hinge domain, CH2 domain and CH3 domain (and further CH4 domain in IgE) connected in this order from the amino terminus.

5 For example, the Fc region used for the chimeric protein may be a continuous sequence from the hinge domain to the CH3 domain of the above sequence. However, from the viewpoint that it should be able to be purified and/or detected with commercially available polyclonal
10 antibodies and/or monoclonal antibodies, protein A, protein G or the like, the hinge domain is not essential, and it may partially contain a mutation such as deletion and insertion of one or more amino acid residues. Further, while the immunoglobulin may be derived from
15 any animals including human and mouse, one derived from mouse can be used, for example. Although the subtype of the immunoglobulin may be any subtype, IgG can be used, for example. The subclass may also be any subclass, and IgG1, IgG2a and so forth can be mentioned, for example.
20 Exemplary amino acid sequences of the chimeric protein of the present invention are shown in SEQ ID NOS: 7 and 14. In SEQ ID NOS: 7 and 14, it is presumed that 16 amino acid residues at the N-terminus constitute a signal peptide.

25 The chimeric protein of the present invention can be produced by allowing expression of a chimeric gene coding for it (chimeric protein gene) in a suitable cell.

A chimeric protein gene can be prepared by obtaining a glycoprotein Iba chain gene and an immunoglobulin heavy chain gene respectively from a cDNA library, genomic library, DNA fragment or the like using genetic engineering techniques or chemically preparing them, and ligating them.

A glycoprotein Iba chain gene can be obtained from, for example, a cDNA library produced by using a phage vector or the like from mRNA of HEL cell, which is a human megakaryocyte cell strain, through reverse transcription PCR using suitable primer DNA designed based on a known DNA sequence of glycoprotein Iba chain gene. Further, a clone containing a glycoprotein Iba chain gene can be obtained from such a cDNA library by performing hybridization using a probe DNA designed based on the known DNA sequence. Alternatively, it can be obtained by excising it from plasmid containing a glycoprotein Iba chain gene registered at ATCC (American Type Culture Collection, pGPIb2.4, deposition number: ATCC65755) with a suitable restriction enzyme.

A gene of immunoglobulin heavy chain can be obtained from, for example, cDNA prepared from mRNA of mouse immunoglobulin producing hybridoma, a cDNA library produced by using a phage vector or the like through reverse transcription PCR using suitable primer DNA designed based on a known DNA sequence of the immunoglobulin heavy chain gene. Further, a clone

containing a mouse immunoglobulin gene can be obtained from such a cDNA library by performing hybridization using a probe DNA designed based on the known DNA sequence.

5 A chimeric protein gene can be obtained by digesting DNA strands of a full length glycoprotein Iba chain gene or a partial sequence thereof and a full length mouse immunoglobulin heavy chain $\gamma 1$ gene or $\gamma 2a$ gene or a partial sequence thereof with a suitable
10 restriction enzyme and then ligating them. The digestion and the ligation of the both genes may be performed so that the ligation product should code for a chimeric protein consisting of an Fc region of immunoglobulin molecule fused at its amino terminus to a
15 partial protein comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl terminus. Further, extracellular secretion of the chimeric protein is desired, the segment for glycoprotein Iba chain may contain a signal peptide.

20 A chimeric protein gene produced as described above is expressed by using a suitable host-vector system. As the host, animal cells, insect cells and so forth can be mentioned. The vector is not particularly limited so long as it can function as a vector in the
25 host cell, and it is preferable to use an expression vector having a promoter suitable for the host cell. A chimeric protein can be produced by transforming the

host cell with a recombinant vector obtained by inserting a chimeric protein gene into an expression vector, and culturing the transformed cell.

While a chimeric protein produced as described above may be used as it is, it can be readily purified by utilizing the Fc region of immunoglobulin molecule through affinity chromatography using immobilized protein A, protein G, anti-immunoglobulin antibodies and so forth.

10

<2> Method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of this binding

The first method for detecting the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding according to the present invention is characterized in that von Willebrand factor is immobilized in a reaction vessel in the presence of a substance inducing the binding of von Willebrand factor and glycoprotein Ib (henceforth also referred to as "binding inducing substance"), and the immobilized von Willebrand factor is allowed to react with the glycoprotein Ib.

15
20

By immobilizing von Willebrand factor in a reaction vessel in the presence of a binding inducing substance, a step of adding a binding inducing substance during the reaction of von Willebrand factor and glycoprotein Ib in a liquid phase can be omitted.

25

von Willebrand factor can be prepared from human blood according to the method described in H.R. Gralnick et al., *J. Clin. Invest.*, 62, 496 (1978) or the like.

5 As the binding inducing substance, there can be mentioned botrocetin, ristocetin and so forth, and botrocetin is preferred.

10 As the reaction vessel in which von Willebrand factor is immobilized, a vessel made of synthetic resin such as polystyrene and polycarbonate or glass may be used. More specifically, a 96-well multi-well plate made of polystyrene and so forth can be mentioned. By injecting a solution containing von Willebrand factor into the aforementioned reaction vessel, von Willebrand factor can be immobilized on a wall surface of the vessel. It is also possible to immobilize collagen on a wall surface of the reaction vessel, and allow von Willebrand factor to bind to the collagen. The conditions for immobilizing von Willebrand factor or collagen to a reaction vessel are not particularly limited so long as they can be immobilized. However, 20 when a vessel made of polystyrene is used, for example, it is preferable to use a neutral solution, preferably at pH 6.8-7.8, more preferably at about pH 7.4.

25 For the immobilization of von Willebrand factor, while a solution containing von Willebrand factor and a solution containing a binding inducing substance may be separately added to a reaction vessel, it is preferable

to prepare a solution containing both of von Willebrand factor and a binding inducing substance, and add it into the reaction vessel, from the viewpoint of operation efficiency. Further, a reaction vessel in which von Willebrand factor is immobilized is preferably added with a bovine serum albumin solution or the like to block unbound areas on the wall surface.

After von Willebrand factor is immobilized in a reaction vessel, the reaction vessel is washed and then glycoprotein Ib is added. Upon addition of glycoprotein Ib, the binding reaction of von Willebrand factor and glycoprotein Ib is caused. This reaction is attained in a liquid phase. Subsequently, the binding of von Willebrand factor and glycoprotein Ib is detected. This detection can be performed by the method usually used for detection of the binding of von Willebrand factor and glycoprotein Ib.

The second method according to the present invention is a method wherein the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding is detected by allowing the aforementioned chimeric protein or the chimeric protein labeled with a labeling substance to bind to von Willebrand factor immobilized in a reaction vessel, and detecting the Fc region of the immunoglobulin molecule or the labeling substance. More specifically, a solution containing von Willebrand factor is added to the reaction vessel to

immobilize the von Willebrand factor on a wall surface of the reaction vessel. Then, a solution containing a chimeric protein is added to the reaction vessel to allow the chimeric protein to bind to the immobilized von Willebrand factor. This binding can be induced by the presence of a binding inducing substance in the reaction system of the von Willebrand factor and the chimeric protein. Specifically, when the aforementioned chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the reaction vessel. For example, von Willebrand factor is immobilized in the reaction vessel in the presence of a binding inducing substance in a manner similar to that of the aforementioned first method, or the binding inducing substance is added at the same time as, or at a time point around the addition of the solution containing the chimeric protein to the reaction vessel.

The chimeric protein binds to the immobilized von Willebrand factor at the von Willebrand factor binding site of glycoprotein Ib contained in the molecule. The detection of the chimeric protein bound to von Willebrand factor as described above can be performed by, for example, detecting the Fc region of the immunoglobulin molecule contained in the molecule. For the detection of the Fc region, a method usually used

for immunoassay can be used.

Specifically, for example, a labeled substance that specifically binds to the Fc region such as protein A, protein G, and anti-immunoglobulin antibodies is added to the reaction vessel, and the label is detected. As the labeling substance, there can be mentioned enzymes such as alkaline phosphatase and peroxidase, biotin, avidin, fluorescent substances such as fluorescein, compounds containing a fluorescent rare earth element such as europium and lanthanoids and so forth. Biotin or avidin is detected by further binding to them another labeling substance bound to avidin or biotin. Enzymes can be detected by adding a suitable substrate to cause an enzymatic reaction and observing visible absorbance, UV absorbance, fluorescence, luminescence etc. Furthermore, fluorescent substances and compounds having a property of emitting fluorescence can be detected based on fluorescence emitted upon irradiation with excitation light.

The chimeric protein bound to the immobilized von Willebrand factor can also be detected by using a chimeric protein labeled with a labeling substance beforehand and detecting this labeling substance. The labeling substance and the detecting method therefor may be similar to those mentioned above for use in the detection of the Fc region. When a chimeric protein labeled with a labeling substance is used, a purified

chimeric protein is preferably used.

The purification of the chimeric protein can be attained by using the Fc region of the immunoglobulin molecule through affinity chromatography and so forth as described above.

The third method according to the present invention is a method wherein the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding is detected by allowing von Willebrand factor or von Willebrand factor labeled with a labeling substance to bind to the chimeric protein immobilized in a reaction vessel, and detecting a partial structure of the von Willebrand factor or the labeling substance. More specifically, a solution containing antibodies that bind to a partial structure of the chimeric protein, preferably antibodies that binds to the immunoglobulin Fc region, protein A or protein G is added to a reaction vessel to immobilize them on a wall surface of the reaction vessel. Then, a solution containing a chimeric protein can be added to the reaction vessel to allow the chimeric protein to bind to the immobilized antibodies, protein A, protein G or the like, thereby preparing a reaction vessel on which the chimeric protein is immobilized. Alternatively, a chimeric protein may be directly immobilized in a reaction vessel. Subsequently, a solution containing von Willebrand factor or von Willebrand factor labeled with a labeling substance is

added to the reaction vessel to allow the von Willebrand factor to bind to the immobilized chimeric protein.

This binding can be induced by adding a binding-inducing substance to a reaction system of the von Willebrand

5 factor and the chimeric protein. Specifically, when the aforementioned chimeric protein is allowed to bind to the von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to reaction vessel.

10 For example, a binding inducing substance is added at the same time as, or at a time point around the addition of the solution containing von Willebrand factor or von Willebrand factor labeled with a labeling substance to the reaction mixture.

15 The von Willebrand factor binds to the immobilized chimeric protein. The von Willebrand factor that binds to the chimeric protein as described above can be detected, for example, by using antibodies that bind to von Willebrand factor. For the detection of the

20 antibodies bound to the von Willebrand factor, a method usually used for immunoassay can be used. Specifically, for example, there can be mentioned methods utilizing beforehand labeling of the antibodies that bind to von Willebrand factor with an enzyme such as alkaline

25 phosphatase and peroxidase, biotin, avidin, fluorescent substance such as fluorescein, compound containing a fluorescent rare earth element such as europium and

lanthanoids or the like. Biotin or avidin is detected by further binding to them another labeling substance bound to avidin or biotin. ~~Enzymes~~ can be detected by adding a suitable substrate to cause an enzymatic
5 reaction and observing visible absorbance, UV absorbance, fluorescence, luminescence etc. Furthermore, fluorescent substances and compounds having a property of emitting fluorescence can be detected by fluorescence emitted upon irradiation with excitation light.

10 The von Willebrand factor bound to the immobilized chimeric protein can also be detected by using von Willebrand factor labeled beforehand with a labeling substance and detecting this labeling substance. The labeling substance and the detecting method therefor may
15 be similar to those used for the detection of the aforementioned antibodies that bind to von Willebrand factor.

 In the aforementioned first, second and third methods, inhibition of the binding of von Willebrand
20 factor and glycoprotein Ib can be detected by comparing a case where a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib (henceforth also referred to as "binding inhibition substance") is added to a reaction vessel at substantially the same time as
25 the addition of glycoprotein Ib (or a chimeric protein) to the reaction vessel or prior to the addition of glycoprotein Ib and a case where the inhibition

substance is not added for the binding of von Willebrand factor and glycoprotein Ib.

Further,~~in the~~ aforementioned first, second and third methods, a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib can be detected by
5 adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or prior to the reaction and detecting inhibition of the binding of von
10 Willebrand factor and glycoprotein Ib. If a standard curve that represents the relation between amount of an inhibition substance and binding of von Willebrand factor and glycoprotein Ib is prepared, the inhibition substance of an unknown amount can be quantified.

15 No low molecular weight compound has been reported so far, which inhibits the binding of von Willebrand factor and glycoprotein Ib and has antithrombotic activity. The methods of the present invention are extremely simpler compared with the conventional methods,
20 and are also useful for search of such a low molecular compound as mentioned above.

<3> Method and kit for measurement of glyocalicin

In the aforementioned first, second and third
25 methods, glyocalicin can be measured by adding a sample containing glyocalicin to the reaction vessel during the reaction of von Willebrand factor and glycoprotein

Ib or prior to the reaction and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib.

If a standard curve that represents the relation between glyocalicin concentration and the binding of von Willebrand factor and glycoprotein Ib is prepared, concentration of glyocalicin in an unknown amount can be measured.

If von Willebrand factor and the chimeric protein are prepared as a kit, the measurement of glyocalicin according to the present invention can conveniently be performed. As such a kit, there can be specifically exemplified a kit comprising von Willebrand factor, a chimeric protein, a binding inducing substance, glyocalicin of a known amount, anti-immunoglobulin antibodies labeled with alkaline phosphatase or the like, a reagent for detecting the label and a washing buffer. As another embodiment, there can be exemplified a kit comprising von Willebrand factor, a chimeric protein labeled with a labeling substance, a binding inducing substance, glyocalicin of a known amount, a reagent for detecting the label and a washing buffer.

<4> Low molecular weight true inhibition substance for binding of von Willebrand factor and glycoprotein Ib

By using the method of the present invention for detecting the inhibition of the binding of von Willebrand factor and glycoprotein Ib described in the

above <2>, a low molecular weight true inhibition substance for binding of von Willebrand factor and glycoprotein Ib can be searched (screened). The term "true inhibition substance" used herein means a substance that specifically inhibits platelet aggregation in plasma involving von Willebrand factor and glycoprotein Ib. A substance that inhibits the binding of von Willebrand factor and glycoprotein Ib in a non-specific manner is not a true inhibition substance, even though it may inhibit the binding of von Willebrand factor and glycoprotein Ib, like substances that generally change structures of proteins such as protein denaturing substances and detergents or substances that non-specifically bind to proteins.

A true inhibition substance can be distinguished by measuring inhibitory activity for von Willebrand factor and glycoprotein Ib dependent platelet aggregation in plasma using ristocetin or botrocetin and inhibitory activity for von Willebrand factor and glycoprotein Ib non-dependent platelet aggregation using collagen or adenosine diphosphate (ADP), and comparing them. That is, a compounds which inhibit von Willebrand factor and glycoprotein Ib dependent platelet aggregation (for example, ristocetin-induced platelet aggregation), and does not substantially inhibit von Willebrand factor and glycoprotein Ib non-dependent platelet aggregation (for example, platelet aggregation

induced by collagen or ADP) at the same concentration is a true inhibition substance for the binding of von Willebrand factor and glycoprotein Ib.

5 The inhibition substance of the present invention preferably inhibit von Willebrand factor and glycoprotein Ib dependent platelet aggregation at a level of 80% or more, more preferably 90% or more, at a concentration of, for example, 1 mM. Further, if inhibition for von Willebrand factor and a glycoprotein
10 Ib non-dependent platelet aggregation is 30% or less, preferably 25% or less, it can be regarded that there is not substantial inhibition.

The term "low molecular weight" preferably means a molecular weight of 2000 or less, more preferably 1000
15 or less. Further, the inhibition substance of the present invention is preferably one that can exert the activity even if it is not a polymer.

Specific examples of low molecular weight antithrombotic substances screened by the method of the
20 present invention include the compounds of the aforementioned structures, more specifically those compounds mentioned below, which were designated as K17427A, K17427B, K17427C and K17427D. These compounds were found in an actinomycete belonging to the genus
25 *Couchioplanes* (*Couchioplanes* sp. AJ9553 (FERM BP-6612)) as substances that had activity of markedly inhibiting the binding of von Willebrand factor and glycoprotein Ib.

The physicochemical properties of these compounds and an exemplary method for producing them will be explained below.

- 5 (1) Physicochemical properties of K17427A, K17427B, K17427C and K17427D

(i) Physicochemical properties of K17427A

Appearance: yellow amorphous solid

Molecular formula: $C_{44}H_{44}O_{14}Cl_2$

- 10 Mass spectrometry (high resolution FAB-MS)

Found: 866.2117 (M)⁺

Calcd.: 866.2108

Specific rotation: $[\alpha]_D^{24}$: -60° (c 0.09, THF)

- 15 Ultraviolet absorption spectrum: λ_{max} (ϵ) 235 (57000), 276 (59500), 427 (25000)

¹H-NMR spectrum (400 MHz, CD₃CO₂D) δ : 7.64 (2H, s), 6.04 (2H, s), 5.38 (2H, s), 3.45 (8H, s), 2.05 (2H, m), 1.28 (6H, d, J=6.8Hz), 1.04 (6H, d, J=6.6Hz), 0.38 (6H, d, J=6.3Hz)

- 20 ¹³C-NMR spectrum (100 MHz, CD₃CO₂D) δ : 205.9 (s), 173.2 (s), 171.8 (s), 162.1 (s), 154.6 (s), 135.5 (d), 134.8 (s), 131.4 (s), 120.8 (s), 120.2 (s), 114.5 (d), 113.1 (s), 111.3 (s), 94.2 (d), 77.6 (s), 55.4 (q), 48.1 (d), 44.3 (d), 35.0 (d), 16.3 (q), 6.7 (q)

- 25 Solubility: easily soluble in dimethyl sulfoxide, pyridine and acetic acid, hardly soluble in water
Structural formula: structure represented by the

aforementioned formula (II)

(ii) Physicochemical properties of K17427B

Appearance: yellow amorphous solid

5 Molecular formula: $C_{43}H_{42}O_{14}Cl_2$

Mass spectrometry (high resolution FAB-MS)

Found: 852.1997 (M)⁺

Calcd.: 852.1952

Specific rotation: $[\alpha]_D^{25}$: -61° (c 0.13, THF)

10 Ultraviolet absorption spectrum (methanol): λ_{max} (ϵ) 235 (41000), 273 (43000), 434 (18500)

¹H-NMR spectrum (400MHz, CD₃CO₂D) δ : 7.81 (2H, s), 6.17 (1H, s), 6.14 (1H, s), 5.54 (1H, s), 5.50 (1H, s), 3.62 (3H, s), 3.58 (3H, s), 3.53 (1H, q, J=7.0Hz), 3.20 (1H, 15 d, J=18Hz), 3.08 (1H, d, J=18Hz), 1.20 (3H, d, J=7.6Hz), 1.17 (3H, d, J=6.7Hz), 1.04 (3H, d, J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 0.52 (3H, d, J=7.0Hz)

Solubility: easily soluble in dimethyl sulfoxide, pyridine and acetic acid, hardly soluble in water

20 Structural formula: structure represented by the aforementioned formula (I) wherein R¹ = R² = Cl and R³ = H

(iii) Physicochemical properties of K17427C

25 Appearance: yellow amorphous solid

Molecular weight (ESI-MS): 799 (M+H)⁺

Ultraviolet absorption spectrum: λ_{max} 234, 281, 418

¹H-NMR spectrum (400 MHz, CD₃OD) δ: 7.59 (2H, d, J=8.4Hz),
7.25 (2H, d, J=8.4Hz), 7.14 (2H, s), 6.05 (2H, s), 5.37

(2H, brs), 3.59 (6H, s), 3.46 (2H, br), 2.12 (2H, m),
1.38 (6H, d, J=5.2Hz), 1.15 (6H, d, J=6.8Hz), 0.64 (6H,
5 br)

Structural formula: structure represented by the
aforementioned formula (I) wherein R¹ = R² = H and R³ =
CH₃

10 (iv) Physicochemical properties of K17427D

Appearance: yellow amorphous solid

Molecular weight (ESI-MS): 833 (M+H)⁺

Ultraviolet absorption spectrum: λ_{max} 234, 276, 423

¹H-NMR spectrum (400 MHz, CD₃OD) δ: 7.77 (2H, s), 7.59
15 (1H, d, J=8.4Hz), 7.26 (1H, d, J=8.4Hz), 7.15 (1H, s),
6.09 (1H, s), 6.08 (1H, s), 5.46 (1H, s), 5.37 (1H, brs),
3.61 (3H, s), 3.54 (4H, s), 3.42 (1H, q, J=7.0Hz), 2.12
(2H, m), 1.39 (3H, d, J=6.8Hz), 1.20 (6H, m), 0.63 (3H,
br), 0.50 (3H, d, J=7.0Hz)

20 Structural formula: structure represented by the
aforementioned formula (I) wherein R¹ = Cl, R² = H and R³
= CH₃

(2) Method for producing K17427A, K17427B, K17427C and
25 K17427D

The inhibition substances for the binding of von
Willebrand factor and glycoprotein Ib of the present

invention, K17427A, B, C and D (henceforth referred to simply as "inhibition substances") can be produced by, for example, culturing an actinomycete belonging to the genus *Couchioplanes*, for example, *Couchioplanes* sp.

5 AJ9553 (FERM BP-6612) using a liquid or solid nutrient medium containing an assimilable carbon source and nitrogen source. As the carbon source of the nutrient medium, carbohydrates such as glucose, sucrose and starch, glycerol and so forth can be preferably used. 10 As the nitrogen source, naturally occurring substances such as yeast extract, peptone, corn steep powder, soybean flour and cotton seed flour (Pharmamedia), amino acids, inorganic nitrogen-containing compounds such as ammonium sulfate and urea and so forth can be used.

15 The culture for the production of the inhibition substances may be performed as culture with shaking or standing culture using a test tube, flask containing the aforementioned nutrient medium or the like, aeration culture with stirring using a jar fermenter, tank 20 containing the aforementioned nutrient medium or the like and so forth. The culture can be performed usually in the range of 20°C to 40°C, preferably 25°C to 37°C.

Extraction of the inhibition substances from culture broth after completion of the culture can be 25 performed by, for example, extraction with a suitable solvent, adsorption of the inhibition substances on an adsorption resin or the like and subsequent elution with

a suitable solvent. Further, purification of the inhibition substances can be performed by combination of techniques such as solvent extraction, chromatography or reversed phase chromatography and so forth utilizing adsorption resin, activated charcoal, ion exchange resin, silica gel etc.

Specifically, for example, cells of *Couchioplanes* sp. AJ9553 (FERM BP-6612) strain are extracted with acetone, acetone is evaporated from the extract, and the residue is suspended in water. The aqueous suspension is adjusted to pH 2, and then ethyl acetate is added to extract it. The ethyl acetate layer is concentrated under reduced pressure, and the obtained residue is fractionated by anion exchange chromatography. For example, the residue can be dissolved in water-containing methanol, adsorbed on a column filled with DIA ION HP-20 (Mitsubishi Chemical), and eluted with methanol. Then, an inhibition substance is obtained by fractionation of the eluate by HPLC using an ODS column, or fractionation by silica gel TLC. To which one of the compounds mentioned above the obtained inhibition substance corresponds can be determined by examining the aforementioned physicochemical properties.

25

Brief Explanation of the Drawings

Fig. 1 outlines the construction of GPIb-mIgG1Fc

expression system.

Fig. 2 outlines the construction of GPIb-mIgG2aFc
expression system.

Fig. 3 shows binding amount of immobilized von
5 Willebrand factor and a chimeric protein plotted against
amount of botrocetin (ELISA).

Fig. 4 shows activity of inhibition substance for
the binding of von Willebrand factor and a chimeric
protein (ELISA).

10 Fig. 5 shows activity of inhibition substance for
the binding of von Willebrand factor and a chimeric
protein (Eu-labeling method).

Fig. 6 shows exemplary quantification of
glycocalicin in human plasma (ELISA).

15 Fig. 7 shows exemplary quantification of
glycocalicin in human plasma (Eu-labeling method).

Fig. 8 shows activity of inhibition substance for
the binding of von Willebrand factor and a chimeric
protein (method utilizing presence of botrocetin in
20 liquid phase).

Fig. 9 shows activity of inhibition substance for
the binding of von Willebrand factor and a chimeric
protein (method utilizing immobilized chimeric protein).

Fig. 10 shows activity of inhibition substances
25 K17427A, B, C and D for the binding of von Willebrand
factor and a chimeric protein (Eu-labeling method).

Fig. 11 shows activity of inhibition substances

K17427A, B, C and D for the binding of von Willebrand factor and a chimeric protein (^{125}I -labeling method).

Fig. 12 shows inhibitory activity of K17427A for ristocetin induced-platelet aggregation, and ADP- and collagen-induced aggregation.

Best Mode for Carrying out the Invention

The present invention will be explained more specifically in to the following examples.

Example 1: Preparation of chimeric protein gene

<1> Cloning of glycoprotein Iba chain gene

Cloning of human glycoprotein Iba chain gene was attained by constructing a cDNA library from human erythroleukemia cells (HEL) according to the method described in Molecular Cloning (Sambrook, J., Fritsch, E.F., Maniatis, T., Molecular Cloning, Cold Spring Harbor Laboratory Press (1989)). That is, human erythroleukemia cells were stimulated by culturing them in a medium containing 160 nM of a phorbol ester (phorbol-12-myristate-13-acetate: PMA) for 48 hours, and then the medium was removed. A guanidinium thiocyanate buffer (4.0 M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.5), 1% 2-mercaptoethanol) was added to the cells to suspend the cells in the buffer. The cell suspension was subjected to disruption treatment by using a

Polytron homogenizer (produced by Brinkmann).

Laurylsarcosinate (sodium laurylsarcosinate) was added to the disrupted cell suspension at a final concentration of 0.5%. This solution was centrifuged at 5000 x g for 10 minutes to remove the precipitates. The centrifugation supernatant was overlaid on cesium chloride/EDTA solution (5.7 M CsCl, 0.01 M EDTA, pH 7.5) contained in an ultracentrifugation tube and subjected to ultracentrifugation at 100000 x g for 20 hours. The precipitated RNA was collected and purified by ethanol precipitation to obtain total RNA.

The obtained total RNA was loaded on an oligo-dT cellulose column to obtain mRNA. From 10 µg of this mRNA, single-stranded DNA was prepared by using random hexamer oligo DNA as a primer and a reverse transcriptase, and then double-stranded cDNA was prepared by using a DNA polymerase. An EcoRI adapter was ligated to this cDNA by using T4 DNA ligase. The cDNA to which the adapter was ligated was subjected to a phosphorylation treatment using T4 polynucleotide kinase, and purified by using a gel filtration column. A λgt10 arm prepared so that it could be inserted into an EcoRI restriction site (produced by Stratagene) was ligated to this DNA using T4 DNA ligase. This recombinant DNA was packaged in phage to obtain a cDNA library.

Escherichia coli NM514 was infected with this phase. Plaque hybridization was performed for the

produced phage plaques by using oligo DNA (SEQ ID NO: 1) end-labeled with a radioisotope (^{32}P) as a probe. That is, the produced phage plaques were transferred to a nitrocellulose filter, and DNA was denatured with an
5 alkaline denaturation solution (0.5 M sodium hydroxide, 1.5 M sodium chloride). The filter was neutralized with a neutralization solution (0.5 M Tris-HCl, pH 7.0, 1.5 M sodium chloride), and heated at 80°C for 2 hours to immobilize the DNA on the filter. Synthesized DNA
10 (chemically synthesized by using a DNA synthesizer Model 380A produced by Perkin-Elmer Applied Biosystems) was labeled at the 5' end of the DNA with γ - ^{32}P -ATP with the aid of T4 DNA kinase (produced by Takara Shuzo), and used as probe DNA. The nucleotide sequence of the
15 aforementioned oligo DNA was designed based on the nucleotide sequence of a known human glycoprotein Iba chain gene (J.A. Lopez et al., *Proc. Natl. Acad. Sci. USA*, 84, 5615-5619 (1987)).

The nitrocellulose filter (diameter: 132 mm) on
20 which phage plaque DNA was transferred was immersed in 4 ml of a hybridization buffer (0.9 M sodium chloride, 0.09 M sodium citrate (pH 7.0), 0.5% sodium laurylsulfate, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin, 100 $\mu\text{g/ml}$ heat-denatured
25 salmon sperm DNA) containing the probe corresponding to 1×10^6 cpm (count per minute) per one filter, and allowed to hybridize at 42°C for 16 hours. The filter

was washed three times with 1 x SSC (0.875% sodium chloride, 0.441% sodium citrate, pH 7.0) and 0.1% sodium laurylsulfate solution at 37°C for 30 minutes to remove the probe non-specifically adsorbed on the filter.

5 After the filter was dried, radioautography was performed by using an X-ray film. As a result, four strains of positive clones were obtained.

The phage was isolated from each positive clone, and *Escherichia coli* NM514 was infected with the
10 isolated phage and proliferated. Then, phage DNA from each clone was purified by cesium chloride density gradient ultracentrifugation. This phage DNA was digested with a restriction enzyme *EcoRI*, and DNA was purified by agarose electrophoresis. This purified DNA
15 was inserted into the *EcoRI* site of pBluescriptSK- (produced by Stratagene) and used for transformation of the *Escherichia coli* XLIIblue (produced by Stratagene) to obtain a transformant. Plasmid was prepared from the transformant by the alkali SDS method, and the
20 nucleotide sequence of the plasmid DNA was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. It was confirmed that one strain among the obtained positive
25 clones contained cDNA of 2.4 kb, and it was the clone having the full length of human glycoprotein Iba gene reported by J.A. Lopez et al. (*Proc. Natl. Acad. Sci.*

USA, Vol. 84, pp.5615-5619 (1987)). This plasmid was designated as pBluescriptGPIbAlpha.

<2> Cloning of gene coding for Fc region of
5 immunoglobulin (γ 1 origin)

The gene for the Fc region of mouse immunoglobulin γ 1 was obtained by extracting total RNA from a mouse hybridoma cell strain MB40.3 and performing reverse transcription PCR. That is, from 10 ml of culture broth
10 of MB40.3 cells, the cells were collected by centrifugation, and the cells were lysed with ISOGEN (1 ml, produced by Nippon Gene). The lysate was subjected to syringing using an injection needle of 18G. The
15 lysate was left for 5 minutes, then added with 200 μ l of chloroform and mixed. The mixture was left stand for 2 minutes and then centrifuged (15000 rpm, 15 minutes) to recover an aqueous phase. The aqueous phase was added
20 with 500 μ l of 2-propanol, mixed, left stand for 5 minutes and centrifuged (15000 rpm, 15 minutes) to precipitate the total RNA. The total RNA was washed with 75% ethanol and dissolved in 100 μ l of sterilized water.

cdNA was prepared by using 3 μ g (20 μ l) of MB40.3 cell total RNA prepared as described above as a template
25 and using random primers and reverse transcriptase (Superscript II produced by GIBCO). The cdNA was amplified by PCR using the primers of SEQ ID NOS: 2 and

3, digested with HindIII and BamHI, purified by agarose gel electrophoresis, and ligated to pGEM-3Zf (produced by Promega) digested with HindIII and BamHI. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant DNA. One of the obtained transformants was cultured. Plasmid was prepared by the alkali SDS method, and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. The obtained nucleotide sequence of the gene fragment for the Fc region of mouse immunoglobulin $\gamma 1$ is shown in SEQ ID NO: 4. This plasmid was designated as pGEMmIgG1Fc.

15

<3> Preparation of plasmid expressing chimeric protein (GP1b-mIgG1Fc)

A chimeric protein comprising the human glycoprotein Ib gene and the Fc region of mouse immunoglobulin $\gamma 1$ obtained as described above, which were fused together, was prepared as follows.

First, the plasmid pBluescriptGP1Alpha containing the glycoprotein Ib α chain gene was digested with restriction enzymes EcoRI and XbaI, and separated by agarose gel electrophoresis to recover DNA of about 1000 bp, which corresponded to the N-terminus region of glycoprotein Ib α chain gene. This was inserted into the

EcoRI-XbaI site of pBluescriptSK- (produced by Stratagene) to prepare plasmid pBluescriptGPIbEX.

Separately, the plasmid ~~pGEMmIgG1Fc~~ containing the partial gene of mouse immunoglobulin $\gamma 1$ obtained as described above was digested with a restriction enzyme XbaI and separated by agarose gel electrophoresis to recover the IgG1Fc gene of 700 bp. This DNA was ligated to pBluescriptGPIbEX digested with a restriction enzyme XbaI and subjected to CIAP treatment to obtain plasmid pBluescriptGPIbIgG1FcFH. The protein encoded by this gene was designated as GPIb-mIgG1Fc, of which gene sequence and amino acid sequence are shown in SEQ ID NOS: 6 and 7, respectively. In SEQ ID NO: 6, it is presumed that the 16 amino acid residues of the N-terminus constitute a signal peptide.

Further, pBluescriptGPIbIgG1FcFH was digested with a restriction enzyme XhoI, and DNA coding for GPIbFcFH was separated by agarose gel electrophoresis. This DNA was inserted into the XhoI site of an expression vector for animal cells pSD(X) to obtain an expression vector pSDGPIbIgG1FcFH, in which the GPIb gene was inserted downstream from a promoter. The outline of the aforementioned procedure is shown in Fig. 1.

Escherichia coli XLIIblue (*Escherichia coli* AJ13434) harboring the plasmid pSDGPIbIgG1FcFH was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology,

Ministry of International Trade and Industry on April 2, 1998, and given an accession number of FERM P-16749.

This was transferred to an international deposit under the provision of the Budapest Treaty on January 11, 1999, and given an accession number of FERM BP-6619.

<4> Cloning of gene coding for Fc region of immunoglobulin (γ 2a origin)

The gene of the Fc region of mouse immunoglobulin γ 2a was obtained by extracting total RNA from a mouse hybridoma cell strain W6/32 and performing reverse transcription PCR. That is, from 10 ml of culture broth of W6/32 cells, the cells were collected by centrifugation, and the cells were lysed with ISOGEN (1 ml, produced by Nippon Gene). The lysate was subjected to syringing using an injection needle of 18G. The lysate was left for 5 minutes, then added with 200 μ l of chloroform and mixed. The mixture was left stand for 2 minutes and then centrifuged (15000 rpm, 15 minutes) to recover an aqueous phase. The aqueous phase was added with 500 μ l of 2-propanol, mixed, left stand for 5 minutes and then centrifuged (15000 rpm, 15 minutes) to precipitate the total RNA. The total RNA was washed with 75% ethanol and dissolved in 100 μ l of sterilized water.

cDNA was prepared by using 3 μ g (20 μ l) of the W6/32 cell total RNA prepared as described above as a

template and using random primers and reverse transcriptase (Superscript II produced by GIBCO). The ~~cDNA~~ was amplified by PCR using primers having nucleotide sequences of SEQ ID NOS: 8 and 9, digested with *Hind*III and *Bam*HI, purified by agarose gel electrophoresis, and ligated to pGEM-3Zf (produced by Promega) digested with *Hind*III and *Bam*HI. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant DNA. One of the obtained transformants was cultured. Plasmid was prepared by the alkali SDS method and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. The obtained nucleotide sequence of the gene fragment for the Fc region of mouse immunoglobulin γ 2a is shown in SEQ ID NO: 10. This plasmid was designated as pGEMmIgG2aFc.

<5> Preparation of plasmid expressing chimeric protein (GPIb-mIgG2aFc)

A chimeric protein gene comprising the human glycoprotein Ib gene and the Fc region of mouse immunoglobulin γ 1 obtained as described above and fused together was prepared as follows.

First, the plasmid pBluescriptGP1Alpha containing the glycoprotein Iba chain gene was digested with

restriction enzymes *EcoRI* and *XbaI*, and separated by agarose gel electrophoresis to obtain a *KpnI-XbaI* DNA fragment containing the sequence of glycoprotein ~~Ib~~ gene for the sequence of from the N-terminus to the 319th aspartic acid.

Further a gene fragment of the Fc region of mouse immunoglobulin $\gamma 2a$ having an *XhoI* site at the 5' end side and an *XbaI* site at the 3' end side was produced by PCR (annealing temperature: 55°C, 30 cycles) using the plasmid pGEMmIgG2aFc containing the partial gene of mouse immunoglobulin $\gamma 2a$ obtained as described above, two kinds of synthetic primers having the nucleotide sequences shown in SEQ ID NOS: 9 and 12 and PFU (produced by Stratagene). This gene fragment was digested with *XbaI* and *XhoI*, then purified by agarose gel electrophoresis and ligated to pBluescriptSK- digested with *XbaI* and *XhoI*. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant plasmid. Plasmid was prepared from the obtained transformant by the alkali SDS method, and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. As a result, it was confirmed to have a nucleotide sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 10 of which 6 nucleotides at the 5' end was replaced

with TCTAGAC and 6 nucleotides at the 3' end was eliminated. This plasmid was designated as pBluescriptmIgG2a. This plasmid was ~~was~~ digested with XbaI and XhoI, and purified by agarose gel electrophoresis to obtain a XbaI-XhoI fragment of the Fc region gene of mouse immunoglobulin γ 2a.

The KpnI-XbaI fragment of human glycoprotein Ib gene and the XbaI-XhoI fragment of Fc region gene of mouse immunoglobulin γ 2a obtained as described above were ligated to pBluescriptSK- digested with KpnI and XhoI, and *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant plasmid. One of the obtained transformants was cultured, and plasmid was prepared by the alkali SDS method to obtain plasmid containing a gene coding for a protein (chimeric protein) comprising the N-terminus side region of glycoprotein Ib (amino acid numbers 1-319, including a signal peptide) and the Fc region of mouse immunoglobulin γ 2a bound together (SEQ ID NO: 13). This plasmid was designated as pBluescriptGPIbFc2a, and the encoded chimeric protein corresponding to the gene was especially designated as GPIb-mIgG2aFc, of which amino acid sequence was shown in SEQ ID NO: 14. In SEQ ID NO: 14, it is presumed that 16 amino acid residues of the N-terminus constitute a signal peptide. *Escherichia coli* XLIIblue (*Escherichia coli* AJ13432) harboring the plasmid pBluescriptGPIbFc2a was deposited at the

National Institute of Bioscience and Human-Technology,
Agency of Industrial Science and Technology, Ministry of
International Trade and Industry on March 19, 1998, and
given an accession number of FERM P-16719. Then, it was
5 transferred to an international deposit under the
provisions of the Budapest Treaty on January 11, 1999,
and given an accession number of FERM BP-6618.

pBluescriptGPIbFc2a was digested with *Xho*I, and
purified by agarose electrophoresis. This *Xho*I fragment
10 containing a gene of the chimeric protein was ligated to
the *Xho*I site of the same animal cell expression vector
pSD(x) as the above <3> to obtain plasmid pSDGPIbFc2a.
Further, pGPIbFcbluescript was digested with *Eco*RI and
*Xho*I, and the *Eco*RI-*Xho*I fragment containing the
15 chimeric protein gene was inserted into the *Eco*RI-*Xho*I
site of expression vector pMikNeo(+) for animal cells
(kindly provided by Dr. K. Maruyama, the Institute of
Medical Science, the University of Tokyo) having SR α
promoter (K. Maruyama and Y. Takebe et al., *Medical*
20 *Immunology*, 20, 27-32, 1990) to obtain plasmid
pMikGPIbFc. The outline of the procedure used for
obtaining pMikGPIbFc is shown in Fig. 2.

Example 2: Production of chimeric protein (GPIb-mIgG1Fc)
25 using animal cells

Cells producing the chimeric protein were produced
as follows. CHOdhr⁻ cells were cultured by using D-MEM

medium (10 ml, produced by GIBCO) containing 10% fetal bovine serum at 37°C under 5% CO₂ at a density of 5 x 10⁵ cells per 10-cm dish. The cells were transfected with pSDGPiB-IgG1Fc prepared as described in Example 1 <3>. The transfection was performed by using calcium phosphate as described below. That is, about 10 µg per 10-cm dish of pSDGPiB-IgG1Fc was added to 0.5 ml of BES buffer (pH 6.96) containing 0.125 M calcium chloride, uniformly added dropwise to a dish, and incubated overnight at 35°C under 3% CO₂. Then, the dish was washed twice with PBS, and further incubated in α-MEM medium not containing nucleic acid at 37°C for about 24 hours under 5% CO₂. The cells transfected as described above were further cultured in α-MEM medium not containing nucleic acids, but containing 0.05 µM methotrexate (MTX) and 10% fetal bovine serum to obtain chimeric protein producing cells.

The chimeric protein producing cells obtained as described above were cultured in an F175 cell culture flask containing α-MEM medium not containing nucleic acid, but containing 0.05 µM methotrexate (MTX) and 10% fetal bovine serum, until about 60% confluent. Then, the medium was exchanged with a serum-free medium, ASF104 medium (produced by Ajinomoto), containing 0.05 µM methotrexate (MTX), and the culture supernatant was collected four days later.

Example 3: Production of chimeric protein (GPIb-
mIgG2aFc) using animal cells

Cells producing the chimeric protein were produced as follows. CHOK1 cells were cultured by using D-MEM medium (10 ml, produced by GIBCO) containing 10% fetal bovine serum at 37°C under 5% CO₂ at a density of 5 x 10⁵ cells per 10-cm dish. The cells were transfected with pMikGPIbFc prepared in Example 1. The transfection was performed by the calcium phosphate method as described below. That is, about 10 µg per 10-cm dish of pMikGPIbFc was added to 0.5 ml of BES buffer (pH 6.96) containing 0.125 M calcium chloride, uniformly added dropwise to a dish, and incubated overnight at 35°C under 3% CO₂. Then, the dish was washed twice with PBS, and further incubated in D-MEM medium at 37°C for about 24 hours under 5% CO₂. The cells transfected as described above were further cultured in D-MEM medium containing G418 (850 µg/ml) and 10% fetal bovine serum to obtain chimeric protein producing cells, which were G418 resistant cells.

The chimeric protein producing cells obtained as described above were cultured in an F175 cell culture flask containing D-MEM medium containing G418 (800 µg/ml) and 10% fetal bovine serum until about 60% confluent. Then, the medium was exchanged with a serum-free medium, ASF104 medium (produced by Ajinomoto), containing G418 (800 µg/ml), and the culture supernatant

was collected four days later.

The collected culture supernatant was centrifuged to remove the solid, and then 160 ml of the supernatant was passed through a Protein A Hitrap (1 ml, produced by Pharmacia) column washed with 20 mM phosphate buffer (pH 7.0) so that the chimeric protein should be adsorbed on the column. The column was sufficiently washed with 20 mM phosphate buffer (pH 7.0), and then eluted with 0.1 M citrate buffer (pH 4.5). The elution of the chimeric protein was performed with detection by a UV monitor at 280 nm, and chimeric protein eluted fractions were immediately neutralized by adding 1 M Tris-HCl buffer (pH 8.5). As a result of SDS electrophoresis, the chimeric protein obtained as described above was found to be a protein having a molecular weight of about 80 kDa as a reduced form and a molecular weight about twice as much as that of the reduced form as non-reduced form.

Example 4 Detection of binding of chimeric protein to
immobilized mixture of von Willebrand factor and
botrocetin

<1> Detection of binding of chimeric protein by ELISA using anti-mouse IgG-Fc antibodies

Botrocetin was obtained from 1 g of lyophilized product of crude venom of *Botrops jararaca* (produced by Sigma) by purification according to the method reported by Read (M.S. Read et al., *Proc. Natl. Acad. Sci. USA.*,

75, 4514-4518, 1978).

Immobilization of a mixed solution of von Willebrand factor and botrocetin on a 96-well multititer plate was attained as follows. First, a physiological saline solution of von Willebrand factor (250 $\mu\text{g/ml}$) and a physiological saline solution of botrocetin (500 $\mu\text{g/ml}$), which were prepared in a conventional manner, were appropriately diluted, and mixed at the concentration ratios shown in Fig. 2. Then, 50 μl of each mixture was added to each well of a 96-well multititer plate (Maxisorp, produced by Nunc). The plate was left stand overnight at 4°C, and then each well was washed once with a physiological Tris buffer (150 μl , 20 mM Tris-HCl (pH 7.4), 0.15 M sodium chloride; Tris buffered saline, referred to as "TBS" hereinafter). Then, each well was added with 100 μl of TBS containing 10% BSA (bovine serum albumin), left stand for about 3 hours, and washed 3 times with TBS to obtain a von Willebrand factor immobilized plate.

Each well of the plate on which von Willebrand factor was immobilized in the presence of botrocetin as described above was added with 25 μl of TBS containing 1% BSA and 25 μl of a solution prepared by diluting 8 times the culture supernatant of the chimeric protein (GPIb-mIgG1Fc) producing cells obtained by using the serum free medium with TBS containing 1% BSA, incubated at room temperature for 1 hour, and washed 3 times with

TBS (150 μ l) containing 0.05% Tween-20. Anti-mouse IgG-Fc goat polyclonal antibodies (Catalog No. 55482, produced by Organon-Teknika) were biotinylated by using Biotin Labeling Kit (Catalog No. 1418165, produced by Boehringer Mannheim) according to the protocol attached to the kit. 50 μ l of 0.1% BSA/TBA solution containing about 2 μ g/ml of the above biotinylated anti-mouse IgG-Fc antibodies was added to each well of the plate, and incubated at room temperature for 1 hour. Further, each well was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20, added with 50 μ l of a solution of the reagent (mixture of biotinylated alkaline phosphatase and streptavidin) contained in VECTASTAIN ABC kit (kit for biotin detection, Alkaline phosphatase standard, Catalog No. AK-5000, produced by Vector Laboratories), which solution was prepared in 0.1% BSA/TBS at 1/5 concentration of that used in the method specified in the manual, and incubated at room temperature for 1 hour. Each well was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, and added with 100 μ l of 100 mM NaHCO₃ solution containing 10 mM MgCl₂, in which p-nitrophenylphosphate was dissolved at 1 mg/ml, to carry out the color development reaction for about 1 hour. After the color development, absorbance at 405 nm was measured. As shown in Fig. 3, the binding of the chimeric protein was observed in a botrocetin and von Willebrand factor amount dependent manner.

<2> Detection of chimeric protein binding using europium
(Eu)-labeling method

The chimeric protein (GPIb-mIgG2aFc) solution
5 purified by the Protein A column, which was obtained in
Example 3, was dialyzed against physiological saline.
The solution of about 200 $\mu\text{g}/1.5\text{ ml}$ was concentrated to
780 μl (concentration of about 250 $\mu\text{g}/\text{ml}$) by
ultrafiltration using Centricon-10 (produced by Amicon).
10 500 μl of the concentrated solution (containing about
125 μg of GPIb-mIgG2aFc) was added with 50 μl of 0.5 M
NaHCO₃, then added with 50 μl of a solution obtained by
dissolving 0.2 mg of Eu-Labeling Reagent (europium DTTA-
isothiocyanate as compound, DELFIA 1244-302, produced by
15 Wallac) in 250 μl of physiological saline, and stirred
at room temperature for about 40 hours to allow the
reaction of europium DTTA-isothiocyanate.

The above reaction mixture was subjected to gel
filtration using HiLoad16/60 Superdex 75pg (inner
20 diameter of 16 mm, length of 60 cm, produced by
Pharmacia) to separate the unreacted reagent and the
chimeric protein. The gel filtration was performed at a
flow rate of 1 ml/minute by using physiological saline
as the eluant. The chimeric protein labeled with Eu was
25 recovered in fractions of the elution volume of 40 to 48
ml. The protein was quantified by using a protein assay
kit (Protein Assay, produced by Bio-Rad) and IgG as a

standard substance. As a result, the concentration of the labeled chimeric protein in the eluted solution had a concentration of 6.4 $\mu\text{g/ml}$. Hereafter, the following experiments were conducted by using this value as the chimeric protein concentration.

The binding of the europium (Eu) labeled chimeric protein and the von Willebrand factor immobilized in the presence of botrocetin prepared as described above was detected as follows. According to the method mentioned in Example 4 <1>, a mixed solution (TBS) containing 2.5 $\mu\text{g/ml}$ of von Willebrand factor and 2.5 $\mu\text{g/ml}$ of botrocetin was added to each well of a 96-well multititer plate (microtitration plate DELFIA, 1244-550, produced by Wallac), immobilized overnight and subjected to washing, blocking and washing to prepare a von Willebrand factor immobilized plate.

Each well of the above plate was added with 25 μl of an assay buffer containing 0.5% BSA (Assay Buffer, Wallac DELFIA 1244-106, produced by Wallac, Composition: 0.5% BSA, 0.05% bovine γ -globulin, 0.01% Tween-40, 20 μM DTPA (diethylenetriamine tetraacetic acid), 50 mM Tris-HCl buffered saline (pH 7.8), 0.05% sodium azide) or the recombinant AS1051 (in which Cys81 was replaced with Ala, N. Fukuchiet al., WO 95/08573) at a final concentration of 20 $\mu\text{g/ml}$ as the binding inhibition substance, further added with 25 μl of a solution of europium (Eu) labeled chimeric protein in the same assay buffer (100 ng/ml),

shaken for 1 minute for stirring, and then left stand at room temperature for 2 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement buffer, 1244-104, produced by Wallac, Composition: 15 μ M β -NTA (2-naphthoyltrifluoroacetone), 50 μ M TOPO (tri-n-octylphosphine oxide), 1 g/L Triton X-100, 100 mM acetic acid/potassium hydrogen phthalate buffer), and shaken for 1 minute for stirring. Then, the amount of europium (Eu) was measured by using a DELFIA Research fluorophotometer (1230 ARCUS Fluorometer, produced by Wallac, measurement time: 1 second). The measured values (with addition or no addition of the binding inhibition substance) and CV value (deviation, %) are shown in Table 1.

Table 1: Measured value and CV value (%) by Eu-labeling method

Average value of count in control (n=80)	26668 cpm
CV value (%)	6.75%
Average value of count with addition of AS1051 (10 μ g/ml) (n=6)	935 cpm
S/N ratio	28.5

Example 5: Detection of inhibition by binding inhibition substance for binding of von Willebrand factor and chimeric protein

<1> Detection of inhibition for binding of chimeric

protein by ELISA using anti-mouse IgG-Fc antibodies

The detection was carried out in the same manner as that of Example 4 <1>~~except~~ that von Willebrand factor was immobilized by using a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin, and a binding inhibition substance of which inhibitory activity was desired to be measured was added to the reaction of the immobilized von Willebrand factor and the culture supernatant of the chimeric protein producing cells.

As the binding inhibition substance, AJvW-2, which is an anti-human von Willebrand factor monoclonal antibody, and a human glycoprotein Ib binding peptide derived from snake venom of *Crotalus horridus horridus* were used.

The hybridoma producing AJvW-2 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on August 24, 1994, and given an accession number of FERM P-14487. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and given an accession number of FERM BP-5248 (refer to WO96/17078). AJvW-2 can be obtained by culturing this hybridoma.

The aforementioned human glycoprotein Ib binding

peptide corresponded to a single chain peptide obtained from a multi-mer peptide derived from snake venom of *Crotalus*~~*horridus*~~ *horridus* (AS1051) in which 81-cysteine residue was replaced with an alanine residue (variant type AS1051). The variant type AS1051 was obtained by modifying the gene coding for AS1051 so that the 81-cysteine residue should be replaced with an alanine residue, and expressing it in *Escherichia coli*. *E. coli* HB101/pCHA1 (*E. coli* AJ13023) harboring pCHA1 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on August 12, 1994 as an international deposit under the provisions of the Budapest Treaty, and given an accession number of FERM BP-4781 (refer to WO95/08573). AS1051 itself is also a human glycoprotein Ib binding peptide, and it can be detected in the same manner as that for the variant type AS1051.

The inhibitory activities of AJvW-2 and the variant type AS1051 for the binding of the chimeric protein (*i.e.*, glycoprotein Ib) are shown in Fig. 4.

<2> Detection of inhibition for binding of chimeric protein by europium (Eu) labeling method

The detection was carried out in the same manner

as that of Example 4 <2> except that von Willebrand factor was immobilized by using a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin, and a binding inhibition substance of which inhibitory activity was desired to be measured was added to the reaction of the immobilized von Willebrand factor and the chimeric protein labeled with europium (Eu).

As the binding inhibition substance, AJvW-2, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051. The inhibitory activities of the both substances for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 5.

Example 6: Detection of glyocalicin in plasma

<1> Detection of glyocalicin by ELISA using anti-mouse IgG-Fc antibodies

Human plasma was prepared by collecting blood from healthy volunteers using an injection needle of 18G, adding 1/10 volume of 3.8% aqueous sodium citrate solution to the blood, and centrifuging the mixture at 3000 x rpm for 10 minutes to separate a supernatant.

Each human plasma collected independently from three volunteers was successively diluted 2-fold (8 times of dilution in total), and 25 µl of the plasma was added to each well of the plate. Each well of the plate

was further added with 25 μ l of a solution prepared by diluting 8-fold a culture supernatant obtained from culture of the chimeric protein producing cells in a serum-free medium with TBS containing 0.1% BSA, and incubated at room temperature for 1 hour. The subsequent reactions and color development were performed in the same manner as Example 5 <1>, and the average values of the results are shown in Fig. 6.

The blood concentration of glyocalicin in healthy people was reported to be about 2 μ g/ml. On the other hand, the glyocalicin concentration showing 50% binding inhibition in this detection system was about 400 ng/ml. From this fact, it was considered that a glyocalicin amount of 60 ng/ml or more could sufficiently be measured in view of the linearity of the plot.

<2> Detection of glyocalicin using chimeric protein labeled with europium (Eu)

Each human plasma independently prepared in the same manner as the above <1> were successively diluted 2-fold with TBS (8 times of dilution in total), and 25 μ l each of the diluted plasma was added to each well of a von Willebrand factor immobilized plate prepared in the same manner as in Example 5 <1> (microtitration plate DELFIA, 1244-550, produced by Pharmacia Biotech, was used as the base plate). Further, 25 μ l a solution of the chimeric protein labeled with europium (Eu) in

assay buffer prepared in the same manner as in Example 4
<1> (100 ng/ml, Assay Buffer; 1244-106, produced by
Pharmacia Biotech) was added to each well of the plate
for reaction. The subsequent washing and measurement
5 were performed in the same manner as in Example 5 <2>,
and the average values of the results are shown in Fig.
7.

The blood concentration of glyocalicin in healthy
people was reported to be about 2 $\mu\text{g/ml}$. On the other
10 hand, the glyocalicin concentration showing 50% binding
inhibition was about 60 ng/ml in this detection system.
From this fact, it was considered that a glyocalicin
amount of 30 ng/ml or more could sufficiently be
measured.

15

Example 7: Detection of binding of chimeric protein to
immobilized von Willebrand factor in the presence of
botrocetin and detection of binding inhibition by
binding inhibition substance

20 <1> Detection of binding of chimeric protein

A TBS solution (50 μl) containing human von
Willebrand factor (2.5 $\mu\text{g/ml}$) was added to each well of
a 96-well plate, and the von Willebrand factor was
immobilized as a solid phase overnight at 4°C. Each
25 well was washed once with TBS (150 μl) and blocked with
TBS containing 5% BSA for about 3 hours. Each well of
the plate was washed twice with TBS (150 μl), and then

added with 25 μ l of an assay buffer (Assay Buffer, Wallac DELFIA 1244-106, produced by Wallac, composition was mentioned in ~~Example 4~~ <2>) or a recombinant AS1051 (in which Cys81 was replaced with Ala) at a final concentration of 20 μ g/ml, further added with the assay buffer (25 μ l) containing the europium (Eu)-labeled chimeric protein prepared in Example 4 <2> (100 ng/ml) and botrocetin (500 ng/ml), and left stand at room temperature for 3 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 <2>), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second). The measured values (with no addition of sample or addition of the inhibition sample) and CV value (deviation, %) are shown in Table 2.

20

Table 2: Measured value and CV value (%) obtained by method utilizing presence of botrocetin in liquid phase

Average value of count in control (n=80)	70220 counts
CV value (%)	8.2%
Average value of count with addition of AJvW-2 (10 μ g/ml) (n=16)	2014 counts
S/N ratio	35

<2> Measurement of inhibition for binding of chimeric

protein by inhibition substance.

The measurement was performed in the same manner as in Example 7 <1> except that a binding inhibition substance of which inhibition activity was desired to be measured was added.

As the inhibition substance, AJvW-2 mentioned in Example 5 <1>, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051 similarly mentioned in Example 5 <1>, which is a human glycoprotein Ib binding protein, were used.

The inhibitory activities for the binding of the chimeric protein (i.e., glycoprotein Ib) of AJvW-2 and the variant type AS1051 are shown in Fig. 8.

Example 8: Detection of binding of von Willebrand factor to immobilized chimeric protein in the presence of binding inducing substance and detection of binding inhibition by binding inhibition substance

<1> Detection of binding using botrocetin

First, 500 μ l of a solution of human von Willebrand factor in physiological saline (300 μ g/ml) was added with 50 μ l of 0.5 M NaHCO₃, then added with 50 μ l of a solution formed by dissolving 0.2 mg of Eu-labeling Reagent (Europium DTTA-isothiocyanate as compound, DELFIA 1244-302, produced by Wallac) in 250 μ l of physiological saline, and allowed to react at room temperature for about 40 hours with stirring.

The above reaction mixture was subjected to gel filtration using HiLoad 16/60 Superdex 75pg (inner diameter of 16 mm, length of 60 cm, produced by

Pharmacia) to separate unreacted reagents and von Willebrand factor. The gel filtration was performed at a flow rate of 1 ml/minute by using physiological saline as eluate. The human von Willebrand factor labeled with Eu was collected in fractions of 40 to 48 ml of elution volume.

The binding of von Willebrand factor labeled with europium (Eu), which was prepared as described above, and the immobilized chimeric protein in the presence of botrocetin was detected as follows. First, 50 μ l of a solution of anti-mouse immunoglobulin polyclonal antibodies (Catalog No. 55482, produced by Organon Teknika, 1 μ g/ml) in 0.1 M sodium carbonate buffer (pH 9.6) was added to each well of a 96-well multititer plate (microtitration plate DELFIA, 1244-550, produced by Wallac), and the antibodies were immobilized overnight. Then, each well was washed, blocked with TBS (100 μ l) containing 5% BSA, and washed 3 times with TBS (150 μ g/ml). Further, 50 μ l of a solution of the chimeric protein (0.5 μ g/ml) in TBS was added to each well and left stand at room temperature for 3 hours to allow the chimeric protein to bind to the immobilized anti-mouse immunoglobulin antibodies. Thus, a chimeric protein immobilized plate was prepared.

Each well of the chimeric protein immobilized plate was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20. Then, in the same manner-as-mentioned in Example 4 <1>, each well of the plate was added with
5 25 μ l of an assay buffer (Assay Buffer, 1244-106, produced by Wallac, composition was mentioned in Example 4 <2>) or a recombinant AS1051 (in which Cys81 was replaced with Ala) as the inhibition substance at a final concentration of 20 μ g/ml, further added with the
10 assay buffer (25 μ l) containing the europium (Eu)-labeled von Willebrand factor (500 ng/ml) and botrocetin (500 ng/ml), and left stand at room temperature for 3 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with
15 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 <2>), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac,
20 measurement time: 1 second). The measured values (with no addition of sample or addition of the inhibition sample) are shown in Table 3.

Table 3: Measured value obtained by method utilizing immobilization of chimeric protein (in the presence of botrocetin)

Average value of count in control	37267 counts
Average value of count with addition of AJvW-2 (10 μ g/ml)	2339 counts

5 <2> Measurement of inhibition for binding of chimeric protein by inhibition substance

The measurement was performed in the same manner as in Example 8 <1> except that a binding inhibition substance of which inhibition activity was desired to be measured was added.

As the inhibition substance, AJvW-2 mentioned in Example 5 <1>, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051 similarly mentioned in Example 5 <1>, which is a human glycoprotein Ib binding protein, were used.

The inhibitory activities of AJvW-2 and the variant type AS1051 for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 9.

20 <3> Detection of binding using ristocetin

Von Willebrand factor labeled with europium (Eu) and a chimeric protein immobilized plate that were prepared in the same manner as the above <1> were used. Each well of the chimeric protein immobilized plate was washed 3 times with TBS (150 μ l) containing 0.05% Tween-

20. Then, each well of the above plate was added with 25 μ l of the assay buffer (Assay Buffer, 1244-106, produced by ~~Wallac~~ composition was mentioned in Example 4 <2>) or the recombinant AS1051 (in which Cys81 was replaced with Ala) at a final concentration of 20 μ g/ml, further added with an assay buffer (25 μ l) containing von Willebrand factor (500 ng/ml) and ristocetin sulfate (produced by Sigma) at one of various concentrations (2, 1, 0.5, 0.25 and 0 mg/ml), and left stand at room temperature for 2 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, added with 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 <2>), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second). The concentration of ristocetin, count of bound von Willebrand factor, and count of von Willebrand factor bound in the presence of the recombinant AS1051 (final concentration: 20 μ g/ml) are shown in Table 4.

Table 4: Binding amount of von Willebrand factor at various ristocetin concentrations (measured values)

Ristocetin concentration	Binding amount (count)	Binding amount in the presence of inhibition substance (count)
2 mg/ml	46213 counts	6884 counts
1 mg/ml	13327 counts	3015 counts
0.5 mg/ml	3665 counts	1852 counts
0.25 mg/ml	3008 counts	3083 counts
0 mg/ml	2818 counts	3246 counts

Example 9: Screening of substance that inhibits binding of glycoprotein Ib and von Willebrand factor using method of Example 7

A substance that inhibits the binding of glycoprotein Ib and von Willebrand factor was screened by using the method of Example 7. Specifically, it was performed in the same manner as in Example 7 <1> except that a sample of which inhibitory activity was desired to be measured was added. Various compounds, culture broth of actinomycetes, filamentous fungi and so forth or organic solvent extracts thereof were used as samples.

As a result, a substance that markedly inhibited the binding of glycoprotein Ib and von Willebrand factor was found in culture broth of AJ9553 strain of actinomycete collected from soil of Shiki no Mori Koen in Yokohama-shi, Kanagawa-ken, Japan or its organic solvent (butanol and ethyl acetate) extraction fraction.

Example 10: Production, isolation and structural
analysis of inhibition substance using actinomycete

AJ9553 strain

5 <1> Method for producing K17427A and K17427B from AJ9553
strain

The AJ9553 strain was inoculated to 5 ml of a seed
culture medium (containing 0.1% beef extract (produced
by DIFCO), 1% glucose, 1% starch soluble (produce by
Nakarai Tesque), 0.5% corn steep powder (produced by
10 Wako Pure Chemicals), 1% polypeptone (produced by
Dainippon Pharmaceutical), 0.5% yeast extract (produced
by DIFCO) and 0.2% calcium carbonate, pH 7.2) contained
in a test tube, and cultured at 28°C for 6 days with
shaking at 120 rpm. This culture broth was inoculated
15 at a concentration of 2% to 70 ml of culture medium
(containing 2% glycerol, Pharmamedia (produced by
Traders Protein), 1% corn steep powder (produced by
Nakarai Tesque), 0.4% calcium carbonates, 0.3% sodium
sulfate and 0.003% of zinc sulfate heptahydrate, pH 7.0)
20 contained in a 500-ml volume Erlenmeyer flask, and
further cultured at 28°C for 8 days with shaking at 180
rpm.

From the culture broth (1.6 L) obtained as
described above, cells were collected by centrifugation,
25 and acetone (1 L x 2) was added to the cells to extract
them at room temperature for 1 day. The cell debris was
separated by filtration, and then the acetone was

evaporated under reduced pressure. The obtained residue was suspended in water. This aqueous suspension was adjusted to pH 2.0 with 5% hydrochloric acid, and added with ethyl acetate (400 ml x 2) to extract it. The ethyl acetate layer was concentrated under reduced pressure, and the obtained residue (1.3 g) was dissolved in 50% methanol. This solution was eluted with methanol using a column filled with DIA ION HP-20 (Mitsubishi Chemical). The obtained fraction was purified by HPLC using an ODS column (YMC-Pack AM-322) to obtain K17427A (400 mg) and K17427B (40 mg).

<2> Method for producing K17427C and K17427D from AJ9553 strain

The AJ9553 strain was inoculated to 5 ml of a seed culture medium (containing 0.1% beef extract (produced by DIFCO), 1% glucose, 1% starch soluble (produce by Nakarai Tesque), 0.5% corn steep powder (produced by Wako Pure Chemicals), 1% polypeptone (produced by Dainippon Pharmaceutical), 0.5% yeast extract (produced by DIFCO) and 0.2% calcium carbonate, pH 7.2) contained in a test tube, and cultured at 28°C for 6 days with shaking at 120 rpm.

From the culture broth (40 ml) obtained as described above, cells were collected by centrifugation, and acetone (1 L x 2) was added to the cells to extract them at room temperature for 1 day. The cell debris was

separated by filtration, and then the acetone was evaporated under reduced pressure. The obtained aqueous suspension was adjusted to pH 2.0 with 5% hydrochloric acid, and added with ethyl acetate (20 ml x 2) to
5 extract it. The ethyl acetate layer was concentrated under reduced pressure, and the obtained residue was dissolved in 50% methanol. This solution was eluted with methanol using a column filled with DIA ION HP-20 (Mitsubishi Chemical). The obtained fraction was
10 fractionated by preparative silica gel TLC (Merck, n-hexane/ethyl acetate/methanol/water = 60:40:5:0.5) to obtain K17427C (3.2 mg) and K17427D (2.2 mg).

Example 11: Identification and physiological test of actinomycete AJ9553 strain producing low molecular weight substance K17427A, B, C and D, which inhibit binding of glycoprotein Ib and von Willebrand factor
15

The results of taxonomic examination of the AJ9553 strain producing K17427A, B, C and D are shown below.

20

1. Morphological characteristics

After culture on the agar medium defined by ISP (International Streptomyces Project) at 28°C for 14 days, it was found by microscopic observation that substrate
25 mycelia fairly elongated and branched, and exhibited orange color. The zigzag elongation like *Nocardia* strains was not observed. Aerial mycelia were formed

from substrate mycelia, and spore chains were formed after maturation. Sporangia were not formed. Spores were ~~arthrospores~~ in an egg-like shape or single rod-like shape, and they usually had a size of 0.4 to 1 x 1 to 1.5 μm . When matured spores were put into water, the spores had flagella and showed migration property.

2. Growth on various agar media and appearance of cultured actinomycete

10 Growth on various agar media and appearance of the cultured actinomycete (cultured at 28°C for 14 days) are shown in Table 5.

Table 5: Growth on various agar media and appearance of the cultured actinomycete (cultured at 28°C for 14 days)

Medium	Growth	Color of substrate mycelium	Sporangium	Soluble pigment
Yeast-malt agar medium (ISP-2)	Good	Orange	Not formed	Yellow
Oatmeal agar medium (ISP-3)	Good	Dark yellow	Not formed	Yellow
Starch-mineral salt agar medium (ISP-4)	Good	Yellow	Slightly formed	Yellow
Glycerin-asparagine agar medium (ISP-5)	Good	Pale orange	Not formed	Not observed
Tyrosine agar medium (ISP-7)	Good	Reddish brown	Abundantly formed	Dark brown (melanin-like)
Nutrient agar medium	Normal	Reddish orange	Not formed	Yellow
Aqueous agar	Poor	Pale yellow	Abundantly formed	Not observed

3. Growth Temperature

5 Growth states after culture on the oatmeal agar medium for 14 days are represented below.

8°C: No growth	30°C: Good growth
18°C: Slight growth	37°C: Good growth
20°C: Normal growth	42°C: Normal growth
28°C: Good growth	45°C: No growth

10

4. Utilization of carbon source

The strain was cultured at 28°C for 14 days on

Pridham-Gottlieb's agar as a basal medium supplemented with each of the following various saccharides. The growth conditions are shown below. "-" indicates no growth, and "+" indicates normal growth.

5	D-Glucose	+	Raffinose	-
	D-Xylose	+	D-Mannitol	+
	L-Arabinose	+	Inositol	-
	L-Rhamnose	+	Sucrose	+
	D-Fructose	+	D-Galactose	+

10

5. Cell components

There were found meso-diaminopimelate, 3-OH-diaminopimelate, glycine and lysine in the cell wall, and the cell fluid type was considered to be VI type.

15 The total cell saccharide components, which constitute a taxonomic characteristic, were arabinose and xylose, and hence the saccharide pattern was D type. The major menaquinone was MK-9 (H4). Further, the acyl type of the cell wall peptidoglycan was glycolyl type.

20

6. Nucleotide sequence analysis of 16S ribosome RNA

Nucleotide sequence analysis of 16S ribosome RNA of this strain revealed that this strain was most close to *Couchioplanes caeruleus* belonging to the family

25 *Micromonosporaceae*.

Based on the above, it was clear that the strain

belonged to the genus *Couchioplanes* among actinomycetes, and thus the AJ9553 strain was decided to be referred to as *Couchioplanes* sp. AJ9553.

This strain was deposited at the National
5 Institute of Bioscience and Human-Technology, Agency of
Industrial Science and Technology, Ministry of
International Trade and Industry (postal code: 305-8566,
1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan)
on January 6, 1999 under the provisions of the Budapest
10 Treaty, and given an accession number of FERM BP-6612.

In the present invention, derivatives of
Couchioplanes sp. AJ9553 such as variant strains thereof
can also be used for the production of the inhibition
substance so long as they have a property for producing
15 an inhibition substance, even though they have
physiological characteristics different from those of
the strain. A variant strain can be obtained by
mutating *Couchioplanes* sp. AJ9553 by means of a usual
method for mutagenizing a bacterial strain, for example,
20 irradiation treatment such as irradiation with X-rays or
ultraviolet rays, treatment with a mutagenizing agent
such as nitrogen mustard, azaserine, nitrous acid, 2-
aminopurine and N-methyl-N'-nitrosoguanidine (NTG),
contact with phage, transformation, transfection,
25 conjugation and so forth.

Example 12: Inhibitory activity of K17427A, C and D for binding of glycoprotein Ib and von Willebrand factor

<1> Measurement of inhibitory activity of K17427A, C and D using method of Example 4 for detecting inhibition for binding of glycoprotein Ib and von Willebrand factor

5 The inhibitory activity of the isolated K17427A, C and D for the binding of glycoprotein Ib and von Willebrand factor was measured in the same manner as Example 4, except that a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second) was used for the measurement. The inhibitory activity of each compound for the binding of glycoprotein Ib and von Willebrand factor was shown in Fig. 10.

15 <2> Measurement of inhibitory activity of K17427A, C and D for binding of I^{125} -labeled von Willebrand factor and formalin-fixed platelets

(1) Preparation of fixed platelets

20 Fixed platelets were prepared as follows. 50 ml of blood collected from healthy volunteers using an injection needle of 18G was added with 1/10 volume of 3.8% sodium citrate, divided into two 50-ml disposable tubes (Falcon 2096) in equal volumes, and centrifuged at 900 rpm for 15 minutes at room temperature by using a refrigerated centrifuge (KUBOTA 8800) to collect the supernatant as platelet rich plasma (PRP). PRP was added with an equal volume of 2% paraformaldehyde/PBS,

25

gently stirred and left stand overnight at 4°C. The solution was centrifuged at 3000 rpm for 10 minutes using the same refrigerated centrifuge as above, and the supernatant was removed by decantation. The precipitates were added with about 20 ml of PBS and suspended with gentle pipetting. After the centrifugation at 3000 rpm for 10 minutes and suspension with PBS were further repeated twice, and then a PBS solution of the same volume as the original PRP amount was finally obtained and used as fixed platelet suspension.

(2) Purification of von Willebrand factor from human serum

Von Willebrand factor was purified from human serum according to the method to H.R. Gralnick et al. (*J. Clin. Invest.*, 62, 496 (1978)).

(3) Labeling of von Willebrand factor with ^{125}I

In a tube in which labeling with ^{125}I was to be performed, Iodogen (produced by Pierce) was immobilized as a solid phase beforehand by adding 1.5 ml of a solution of Iodgen (0.5 mg/ml) in dichloromethane to the tube and removing the solvent under argon flow. High molecular weight von Willebrand factor (0.19 mg/1.5 ml) obtained by gel filtration was introduced into the reaction tube, added with 18.5 Mbq of Na^{125}I , and allowed

to react at room temperature for 2 minutes. The reaction mixture was applied to a PD10 (produced by Pharmacia Biotech) column blocked with BSA and washed beforehand, and eluted with TBS. The eluate was collected as 0.5-ml fractions, and ^{125}I specific activity of each fraction was measured by using a gamma counter, Packard Multi Prias 4. The fractions containing ^{125}I -von Willebrand factor in a large amount were combined, then divided into several tubes and stored at -80°C until use.

10

(4) Measurement of inhibitory activity of K17427A, C and D for binding of I^{125} -von Willebrand factor to immobilized platelets

A 96-well filter plate, Millipore Multiscreen HV (produced by Millipore, $0.45\ \mu\text{M}$), on which the assay was to be performed, was preliminarily blocked by adding 1% BSA/TBS ($100\ \mu\text{l}$) to each well of the filter and leaving it stand for several hours. Then, $20\ \mu\text{l}$ of a suspension obtained by diluting the aforementioned immobilized platelet suspension 10-fold with TBS and $5\ \mu\text{l}$ of a test sample were added to each well, and $25\ \mu\text{l}$ (about 800,000 cpm) of ^{125}I -von Willebrand factor solution containing $0.8\ \mu\text{g/ml}$ of botrocetin or $2.4\ \text{mg/ml}$ of ristocetin was further added to each well. The filter plate was left stand for 30 minutes. The solution in the wells was filtered by suction, and each well was washed by adding TBS ($100\ \mu\text{l}$) containing 0.05% Tween-20 and sucking it.

The measurement using the gamma counter was performed as follows. Filter pieces were cut from the 96-well filter plate after the above washing by using a punch (produced by Millipore, Model number: MAPK 896 OB), put into 6-ml volume polystyrene tubes respectively, and measured for radiation dose of ^{125}I by using Packard Multi Prias 4. The inhibitory activities of K17427A, C and D are shown in Fig. 11.

As shown in the aforementioned results of <1> and <2>, the inhibitory activities of K17427A, C and D enabled the detection with higher sensitivity by the method of <1> (the method of Example 4) according to the present invention, compared with the usually and widely used method described in <2>.

Example 13: Inhibitory activity of K17427A for platelet aggregation

50 ml of blood collected from healthy volunteers using an injection needle of 18G was added with 1/10 volume of 3.8% sodium citrate, divided into two 50-ml disposable tubes (Falcon 2096) in equal volumes, and centrifuged at 900 rpm for 15 minutes at room temperature by using a refrigerated centrifuge (produced by TOMY) to collect the supernatant as platelet rich plasma (PRP). The lower layer was further centrifuged at 1500 rpm for 10 minutes at room temperature, and the supernatant was collected as platelet poor plasma (PPP).

The platelet aggregation inhibitory activity of a test sample was measured by using PRP prepared as described above and Hematracer-801 (produced by Niko Bioscience) as a measurement apparatus. A special cuvette for the measurement preliminarily containing a test sample (2.5 to 5 μ l) was added with 100 μ l of PRP and mounted on the measurement apparatus. The sample was stirred for 2 minutes (37°C), added with a aggregation substance solution of 10-fold concentration, and measured for change of light transmission. The light transmitting PRP was taken as 0%, and the light transmitting PPP as 100%. The aggregation inhibition ratio obtained by the inhibition substance was numerically represented according to the following equation.

15

Aggregation inhibition ratio =

$$\frac{100 - (\text{Aggregation ratio with addition of inhibition substance} - \text{Aggregation ratio immediately after addition of aggregation substance})}{(\text{Control aggregation ratio} - \text{Aggregation ratio immediately after addition of aggregation substance})} \times 100$$

As the aggregation inducing substance, ristocetin sulfate (produced by Sigma, final concentration: 1.2 mg/ml), adenosine diphosphate (ADP, produced by MC Medical, final concentration: 10 μ M) and collagen (produced by MC Medical, final concentration: 10 μ g/ml)

were used.

The inhibitory activities of K17427A for the aggregation induced by each aggregation inducing substance are shown in Fig. 12. The aggregation inhibition ratios at various concentrations for platelet aggregation caused by each aggregation inducing substance, which were calculated as described above, are shown in Table 4.

Table 4: Aggregation inhibition ratios at various concentrations of K17427A for platelet aggregation caused by each aggregation inducing substance

	Ristocetin aggregation	ADP aggregation	Collagen aggregation
1 mM	100%	24%	1%
0.5 mM	84%	8%	0%
0.25 mM	0%	7%	-7%

Although K17427A completely inhibited the aggregation induced by ristocetin at a concentration of 500 μ M or higher, it did not substantially inhibit the aggregation induced by ADP or collagen even at 1 mM. While the inhibition activities of K17427B, C and D were not measured, it can readily be estimated that they similarly specifically inhibit only the aggregation induced by ristocetin, from the facts that they have highly analogous structures and they inhibit the binding of glycoprotein Ib and von Willebrand factor as shown in Example 12.

Industrial Applicability

According to the present invention, the binding of
5 glycoprotein Ib and von Willebrand factor or inhibition
thereof can be detected in a simple manner. According
to the method of the present invention, there are
provided a simple method for quantification of
glycocalicin with superior quantification ability, and a
10 simple method for measurement of a substance inhibiting
the binding of von Willebrand factor and glycoprotein Ib
with superior operability.

If von Willebrand factor is immobilized in the
presence of a binding inducing substance such as
15 botrocetin, the binding of von Willebrand factor and
glycoprotein Ib can be observed in a simple manner with
good reproducibility, without adding a binding inducing
substance such as botrocetin or ristocetin to a liquid
phase.

20 Further, by utilizing the chimeric protein of the
present invention, it becomes unnecessary to prepare or
obtain monoclonal antibodies for detection or
quantification of a binding inhibition substance such as
glycocalicin.

25 Moreover, the present invention also provides a
method for preparing a chimeric molecule (chimeric
protein) that comprises a partial protein of

glycoprotein Ib bound to the Fc region of immunoglobulin molecule by using animal cells.